[{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"||Vasopressin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"||Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"||Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"||Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Public Offering","leadProduct":"Terlipressin Acetate","moa":"||Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Thinkequity"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Estrogen receptor (ESR)","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"NeurMedix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ BioVie"},{"orgOrder":0,"company":"BioVie","sponsor":"NeurMedix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ BioVie"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Estrogen receptor (ESR)","graph1":"Neurology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||NFkB\/ERK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Estrogen receptor (ESR)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||NFkB\/ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Estrogen receptor (ESR)","graph1":"Neurology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"OHRO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ OHRO","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ OHRO"},{"orgOrder":0,"company":"BioVie","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ US Department of Defense"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"||MAPK3","graph1":"Endocrinology","graph2":"Preclinical","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"||Vasopressin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"BioVie","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Estrogen receptor (ESR)","graph1":"Neurology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVie \/ BioVie","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ BioVie"},{"orgOrder":0,"company":"BioVie","sponsor":"BioVie","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Estrogen receptor (ESR)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVie \/ BioVie","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ BioVie"}]
Find Clinical Drug Pipeline Developments & Deals by BioVie
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target